Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Evaluatie van een intacte huidtransplantaat bij vissen en zorgstandaard versus standaardzorg alleen bij niet-genezende veneuze beenzweren (THOR)

10 november 2026 bijgewerkt door: Kerecis Ltd.

Een gerandomiseerde, gecontroleerde klinische studie in meerdere centra ter evaluatie van intacte huidtransplantaties bij vissen en standaardzorg versus standaardzorg alleen bij niet-genezende veneuze beenzweren

The purpose of this study is to determine the between-arm difference in the proportion of subjects achieving complete closure of hard-to-heal venous leg ulcers (VLU) between Intact Fish Skin Graft plus standard of care (IFSG/SOC) versus standard of care alone (SOC) over 12 weeks.

Studie Overzicht

Gedetailleerde beschrijving

This is a randomized controlled multicenter clinical trial evaluating intact fish skin grand and standard of care vs. standard of care alone in nonhealing venous leg ulcers. The product classifies as a medical device and consists of a full thickness fish-skin that has been processed using Kerecis™ Limited's proprietary EnviroIntact™ method.

Studietype

Ingrijpend

Inschrijving (Geschat)

150

Fase

  • Fase 4

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • Pennsylvania
      • Monroeville, Pennsylvania, Verenigde Staten, 15146

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Subjects must be at least 18 years of age or older.

  2. Subjects must have a nonhealing venous leg ulcer present for a minimum of 4 weeks and cannot have received more than 52 weeks of high-level compression prior to the initial screening visit.

  3. No visible signs of healing objectively, less than 40% reduction in wound size in the last 4 weeks.

  4. At randomization, subjects must have a target ulcer with a minimum surface area of 1 cm2 and a maximum surface area of 25 cm2 measured post-debridement.

  5. The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:

    1. ABI between 0.7 and ≤ 1.3;
    2. TBI ≥ 0.6;
    3. TCOM ≥ 40 mmHg;
    4. PVR: biphasic.
  6. If the potential subject has two or more ulcers, and they are separated by at least 2 cm post-debridement, the largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer. If the potential subject has two or more ulcers and they are separated by less than 2cm, the entire wound area is designated as the target ulcer.

  7. Subjects must have a Functional Ambulatory Category Score (FACS) of 3 or greater.

  8. Subjects must consent to using the prescribed compression method for the duration of the study.

  9. Subjects must agree to attend the weekly study visits required by the protocol.

  10. Subjects must be willing and able to participate in the informed consent process.

Exclusion Criteria:

  1. The potential subject is known to have a life expectancy of < 6 months.
  2. The index ulcer is determined to be due to a condition other than venous insufficiency.
  3. The target ulcer exposes muscle, tendon, or bone.
  4. The target ulcer exhibits overt clinical signs and symptoms of infection with cellulitis surrounding the wound margin.
  5. The target ulcer has known or suspected skin malignancy.
  6. The target ulcer has been previously exposed to radiation.
  7. The target ulcer duration is greater than one year having received high level compression without closure for a year or more.
  8. The potential subject has end stage renal disease requiring dialysis.
  9. The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).
  10. A potential subject who, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.
  11. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a cellular or tissue-based product (CTP) in the 30 days prior to the initial screening visit.
  12. The potential subject has a malnutrition indicator score <17 as measured on the Mini Nutritional Assessment.
  13. The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.
  14. The surface area of the target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). Digital planimetry is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).
  15. The surface area measurement of the target ulcer decreases by 20% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (SV-1) to the TV-1 visit during which time the potential subject received SOC.
  16. The potential subject has a Functional Ambulatory Category Score (FACS) of less than 3.
  17. The potential subject has a body mass index (BMI) greater than 42
  18. In the last 8 weeks the patient has undergone revascularization (surgical or stenting) to the affected leg.
  19. Venous intervention in the affected limb in the last 30 days.
  20. Presence of any condition (including current drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of or compliance with the study protocol in the judgment of the Investigator.
  21. Pregnancy at enrollment or women who are breastfeeding, or women of childbearing potential who are planning to become pregnant during the time of the study OR are unwilling/unable to use acceptable methods of contraception (birth control pills, barriers, or abstinence).
  22. Know allergy to any of the components of fish skin or bovine collagen.
  23. Participation in a clinical trial involving treatment with an investigational product within the previous 30 days.
  24. A subject with a disorder that would create unacceptable risk of post-operative complications is excluded.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Intact Fish Skin Graft (IFSG) + Standard of Care

Up to 12 visits with Intact Fish Skin Graft (IFSG) + Standard of Care.

Participants will receive weekly applications of MariGen and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

Actieve vergelijker: Standard of Care

Standard of care will be cleaning, debridement, ulcer moisture balance, and offloading.

Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The percentage of target ulcers achieving complete wound closure
Tijdsspanne: [Time Frame: 1-12 Weeks]

The percentage of target ulcers achieving complete wound closure in 12 weeks

[Time Frame: 1-12 Weeks]

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Time to closure
Tijdsspanne: [Time Frame: 1-12 weeks]

The time to closure of the target ulcers over 12 weeks.

[Time Frame: 1-12 weeks]
Percent area change
Tijdsspanne: [Time Frame: 1-12 weeks]

Percentage wound area change from TV-1 to TV-13 measured weekly with digital photographic planimetry and physical examination.

[Time Frame: 1-12 weeks]
Adverse Events
Tijdsspanne: [Time Frame: 1-12 weeks]

The number of adverse events.

[Time Frame: 1-12 weeks]
Change in pain in target ulcer
Tijdsspanne: [Time Frame: 1-12 weeks]

Change in pain in the target ulcer assessed using the Visual Analog Scale VAS scale from TV-1 to TV-13

[Time Frame: 1-12 weeks]
Visits and product applications needed to close the ulcer
Tijdsspanne: [Time Frame: 1-12 weeks]

The number of visits and product applications needed to close the ulcer

[Time Frame: 1-12 weeks]
Quality of life using the Wound quality of Life questionare wQOL
Tijdsspanne: [Time Frame: 1-12 weeks]

Change in quality of life using the wQOL checklist [TV-1, TV-4, TV-8, and TV-12/Final Visit].

[Time Frame: 1-12 weeks]
Determine improvement in Quality of Life - Forgotten Wound Score FWS
Tijdsspanne: [Time Frame: 1-12 weeks]

Quality of Life assessed using the Forgotten Wound Score. The scale has a score of 0 to 100- 100 being the worst outcome meaning the wound bothers the subject most of the time. [TV-1, TV-4, TV-8, and TV-12/Final Visit].

[Time Frame: 1-12 weeks]

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Medewerkers

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

4 november 2024

Primaire voltooiing (Geschat)

1 november 2026

Studie voltooiing (Geschat)

1 maart 2027

Studieregistratiedata

Eerst ingediend

14 november 2024

Eerst ingediend dat voldeed aan de QC-criteria

15 november 2024

Eerst geplaatst (Werkelijk)

18 november 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

13 november 2026

Laatste update ingediend die voldeed aan QC-criteria

10 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren